Spotlight On... Sanofi might not be long for Paris; Carbylan looks for a buyer; and more...

French drugmaker Sanofi ($SNY) is reportedly considering a move from its headquarters in Paris to a suburban outpost south of the city, part of new CEO Olivier Brandicourt efforts to cut costs. Bloomberg, citing sources close to the company, reports that Sanofi has already moved some workers to an office in Gentilly, about 6 kilometers from its HQ, and that moving the roughly 700 employees in its Belle Epoque building in central Paris to the suburbs could save the drugmaker several million euros a year. Story

@FierceBiotechFierceBiotech Radio on GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster. More | Follow @FierceBiotech

@JohnCFierce: Too bad, if so. $SFY has a beautiful building in Paris. And after its recent Gallic eruption, Paris looks like home. Story | Follow @JohnCFierce

> Joe Biden has named Greg Simon to lead the White House's cancer moonshot program, an effort to accelerate oncology research. News

> Struggling biotech Carbylan Therapeutics ($CBYL) has retained Wall Street firm Wedbush PacGrow to help it find strategic alternatives, including a potential sale. More

Medical Device News

@FierceMedDev: GE Healthcare hand-held ultrasound in pilot NHS test, $20M Nigerian health initiative. Article | Follow @FierceMedDev

@VarunSaxena2: The chart is just so darn startling/horrible. (Have mentioned it in stories about opioid abuse-deterrent tech.) More from the NYT | Follow @VarunSaxena2

@EmilyWFierce:  | Follow @EmilyWFierce

> Cash-rich Zimmer Biomet will have $4.7B to spend on M&A over next few years: Analyst. Story

Pharma News

@FiercePharma: UPDATED: Nasdaq exec says biotechs prime Asian unicorns for listings. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: First came the recall, then the FDA plant ban, now the warning letter to Emcure plant for faking data. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: J&J chief Gorsky suffers cuts in bonus, incentive pay, but still racks up $23.8M. News | Follow @CarlyHFierce

> Sanofi CEO considers moving HQ out of Paris to cut costs. Story

> Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing. Article

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.